Abstract
In chronic inflammatory conditions, endothelial cells actively recruit immune cells from the circulation into the underlying tissue and participate in angiogenesis to support the continuous demand for oxygen and nutrients. They do so in response to activation by cytokines and growth factors such as tumour necrosis factor α (TNFα), interleukin-1 (IL-1), vascular endothelial growth factor (VEGF), and fibroblast growth factors (FGFs). Receptor triggering initiates intracellular signal transduction leading to activation of nuclear factor κB (NFκB), mitogen activated protein kinase (MAPK) activity, and nitric oxide and reactive oxygen species production, among others. As a result, adhesion molecules, cytokines and chemokines, and a variety of other genes are being expressed that mediate and control the inflammatory process. In recent years, different classes of drugs have been developed that interfere with selected enzymes involved in the intracellular signalling cascades. In endothelial cell cultures, they exert potent inhibitory effects on the expression of genes, while several studies also report on in vivo effectiveness to confine the inflammatory responses. To prevent undesired toxicity and to improve drug behaviour and efficacy, drug carrier systems have been developed that selectively deliver the therapeutics into the activated endothelial cells. The above subjects are recapitulated to give an overview on the status of development of endothelial cell directed therapeutic strategies to pharmacologically interfere with chronic inflammatory diseases.
Keywords: endothelial cells, chronic inflammation, angiogenesis, signal transduction, drugs, pharmacology, vascular drug targeting
Current Vascular Pharmacology
Title: Molecular Pathways of Endothelial Cell Activation for (Targeted) Pharmacological Intervention of Chronic Inflammatory Diseases
Volume: 3 Issue: 1
Author(s): Joanna M. Kuldo, Ken Ichi Ogawara, Naomi Werner, Sigridur A. Asgeirsdottir, Jan A. A.M. Kamps, Robbert J. Kok and Grietje Molema
Affiliation:
Keywords: endothelial cells, chronic inflammation, angiogenesis, signal transduction, drugs, pharmacology, vascular drug targeting
Abstract: In chronic inflammatory conditions, endothelial cells actively recruit immune cells from the circulation into the underlying tissue and participate in angiogenesis to support the continuous demand for oxygen and nutrients. They do so in response to activation by cytokines and growth factors such as tumour necrosis factor α (TNFα), interleukin-1 (IL-1), vascular endothelial growth factor (VEGF), and fibroblast growth factors (FGFs). Receptor triggering initiates intracellular signal transduction leading to activation of nuclear factor κB (NFκB), mitogen activated protein kinase (MAPK) activity, and nitric oxide and reactive oxygen species production, among others. As a result, adhesion molecules, cytokines and chemokines, and a variety of other genes are being expressed that mediate and control the inflammatory process. In recent years, different classes of drugs have been developed that interfere with selected enzymes involved in the intracellular signalling cascades. In endothelial cell cultures, they exert potent inhibitory effects on the expression of genes, while several studies also report on in vivo effectiveness to confine the inflammatory responses. To prevent undesired toxicity and to improve drug behaviour and efficacy, drug carrier systems have been developed that selectively deliver the therapeutics into the activated endothelial cells. The above subjects are recapitulated to give an overview on the status of development of endothelial cell directed therapeutic strategies to pharmacologically interfere with chronic inflammatory diseases.
Export Options
About this article
Cite this article as:
Kuldo M. Joanna, Ogawara Ichi Ken, Werner Naomi, Asgeirsdottir A. Sigridur, Kamps A.M. Jan A., Kok J. Robbert and Molema Grietje, Molecular Pathways of Endothelial Cell Activation for (Targeted) Pharmacological Intervention of Chronic Inflammatory Diseases, Current Vascular Pharmacology 2005; 3 (1) . https://dx.doi.org/10.2174/1570161052773898
DOI https://dx.doi.org/10.2174/1570161052773898 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Smooth Muscle Cell Pathophysiology and Advanced Glycation End Products (AGEs)
Current Drug Targets Silent Cerebral Damage in Hypertension
Current Hypertension Reviews Hormones and the Autonomic Nervous System are Involved in Suprachiasmatic Nucleus Modulation of Glucose Homeostasis
Current Diabetes Reviews The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Current Clinical Pharmacology Risk and Benefit of Statins in Stroke Secondary Prevention
Current Vascular Pharmacology Pathogenesis and Immune Status in COVID-19 Pneumonia - A Minireview
Coronaviruses A Pictorial Review of Intracranial Haemorrhage Revisited
Current Medical Imaging Evidence-Based Percutaneous Closure of the Left Atrial Appendage in Patients with Atrial Fibrillation
Current Cardiology Reviews Cerebrovascular Complications After Heart Transplantation
Current Cardiology Reviews Physiological Mechanisms of Action of Incretin and Insulin in Regulating Skeletal Muscle Metabolism
Current Diabetes Reviews Oxidative Stress and Psychological Disorders
Current Neuropharmacology Inhibition of RAGE Axis Signaling: A Pharmacological Challenge
Current Drug Targets The Polyamine Pathway as a Potential Target for Vascular Diseases: Focus on Restenosis
Current Vascular Pharmacology Progress in Drug Treatment of Cerebral Edema
Mini-Reviews in Medicinal Chemistry Label-Free Cell Phenotypic Drug Discovery
Combinatorial Chemistry & High Throughput Screening Jak2 and Reactive Oxygen Species: A Complex Relationship
Current Chemical Biology Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem
Current Drug Targets Stable Gastric Pentadecapeptide BPC 157-NO-system Relation
Current Pharmaceutical Design Role of Nitrosative Stress and Poly(ADP-ribose) Polymerase Activation in Diabetic Vascular Dysfunction
Current Vascular Pharmacology The Role of Chymase in Vascular Remodeling and Tissue Fibrosis
Current Hypertension Reviews